Characteristic | Overall | |
---|---|---|
 | n | % |
Number | 24 | Â |
Age | Â | Â |
Range | 35-70 | |
Median | 60 | |
Sex | Â | Â |
Male | 17 | 71% |
Female | 7 | 39% |
Stage | Â | Â |
II | 4 | 16.5% |
III | 16 | 67% |
IV | 4 | 16.5% |
Karnofsky performance status | ||
90% | 7 | 29% |
100% | 16 | 67% |
Unknown | 1 | 4% |
Prior therapy | Â | Â |
None | 17 | 71% |
Temozolomide alone | 1 | 4.1% |
Radiation alone | 2 | 8.3% |
RSA ablation | 1 | 4.1% |
Interferon | 1 | 4.1% |
Temozolomide + | 1 | 4.1% |
Radiation | ||
Temozolomide + | 1 | 4.1% |
Isolated limb infusion |